DVT Prophylaxis in Total Joint Arthroplasty (TKR and THR)

Core Principles & Pathophysiology

• Deep vein thrombosis (DVT) and pulmonary embolism (PE) do not always correlate directly.

• Fatal pulmonary embolism sits at the tip of the clinical pyramid.

• Symptomatic and silent deep vein thromboses form the wide base of the pyramid.

• Total hip replacement (THR) and total knee replacement (TKR) trigger Virchow’s triad:

  • Systemic surgical trauma induces a transient hypercoagulable state.

  • Direct and indirect manipulation of the limb causes vascular wall trauma and intimal damage.

  • Limb positioning and surgical retraction kink major pelvic and femoral veins, causing venous stasis.

• Historical incidence of DVT in 1984 reached 35%.

• Modern multi-modal protocols have driven total rates down to roughly 0.9%.

• Asian populations show lower baseline rates of clinical DVT, aided by warmer climates and peripheral vasodilation (supported by Dr. Agarwala’s Indian data).

Risk Stratification Systems

• Caprini Risk Assessment Model:

  • Validated across general and specialized surgical disciplines.

  • Scores updated in 2013.

  • A score of 5 to 6 or greater defines high risk.

• Parvizi Risk Score:

  • Tailored specifically to orthopedic joint arthroplasty populations.

  • Adjusts for individual host factors to identify high-risk patients.

• Wells Clinical Score:

  • Evaluates clinical signs of lower-extremity DVT.

  • A score greater than 2 indicates a high pre-test probability of acute DVT.

• Major Individual Patient Risk Factors:

  • Age older than 70 years.

  • Personal history of prior venous thromboembolism (VTE/PE).

  • Active malignancy.

  • Documented systemic hypercoagulable states.

  • Previous stroke or acute myocardial infarction.

Multi-Modal Prophylaxis Strategy

• Effective VTE prevention relies on a combination of three approaches:

  • Early mobilization.

  • Mechanical compression.

  • Targeted pharmacotherapy.

1. Early Mobilization and Rapid Recovery

• Rapid recovery protocols are the foundation of modern VTE prevention.

• Have patients stand and ambulate within 2 hours of surgery.

• Early calf pump muscle activation eliminates prolonged post-surgical venous stasis.

2. Mechanical Prophylaxis

• Intermittent pneumatic compression (IPC) and graded compression stockings.

• Maintain a calibrated pressure of 18 mmHg at the ankle.

• Apply continuously throughout the hospital stay.

• Remove devices only when actively walking or bathing.

• Portable mobile compression units match modern anticoagulant drugs in VTE reduction without adding bleeding risk.

Pharmacologic Selection: The Role of Aspirin

• Modern oral anticoagulants (DOACs) are potent but expensive and increase bleeding and drainage risks.

• Potent anticoagulation and persistent wound hematomas correlate directly with an increased risk of periprosthetic joint infection (PJI) (Dr. Javad Parvizi study).

• Aspirin inhibits platelet cyclooxygenase (COX-1) without disrupting secondary fibrin clotting cascades, minimizing hematoma formation.

• Supported by large registry trials from the Knee Society and AAOS covering over 200,000 patients.

• Endorsed directly by both the American Academy of Orthopaedic Surgeons (AAOS) and the American College of Chest Physicians (ACCP).

• Clinical Advantages of Aspirin:

  • Inexpensive.

  • Simple once-daily oral dosing.

  • Well-tolerated with low bleeding risk.

  • Requires no routine laboratory monitoring.

Clinical Prophylaxis Protocol Summary

• Early Mobilization: Ambulate within 2 hours of leaving the operating room.

• Mechanical Compression: 18 mmHg pressure at the ankle until fully mobile.

• Pharmacologic Dosing:

  • Low-Risk Arthroplasty Patients: Low-dose enteric-coated Aspirin (75 mg to 150 mg daily) for 14 days. Take one tablet after dinner.

  • High-Risk Patients: Aspirin for 28 days combined with continuous mechanical compression.